Mallinckrodt PLC Outlook Revised To Negative From Stable; 'BB-' Corp. Credit Rating Affirmed - S&P Global Ratings’ Credit Research

Mallinckrodt PLC Outlook Revised To Negative From Stable; 'BB-' Corp. Credit Rating Affirmed

Mallinckrodt PLC Outlook Revised To Negative From Stable; 'BB-' Corp. Credit Rating Affirmed - S&P Global Ratings’ Credit Research
Mallinckrodt PLC Outlook Revised To Negative From Stable; 'BB-' Corp. Credit Rating Affirmed
Published Aug 11, 2015
4 pages (1471 words) — Published Aug 11, 2015
Price US$ 150.00  |  Buy this Report Now

About This Report

  
Abstract:

Mallinckrodt PLC is acquiring Therakos Inc. for $1.325 billion in a mostly debt-financed transaction. We now expect pro forma leverage of almost 5x by the end of 2016, modestly higher than our prior base-case scenario. We are affirming our 'BB-' corporate credit rating, but revising the outlook to negative from stable. The negative outlook reflects risks to our base case that Mallinckrodt will not be able to reduce leverage to less than 5x by the end of 2016. NEW YORK (Standard&Poor's) Aug. 11, 2015--Standard&Poor's Ratings Services today affirmed its 'BB-'corporate credit rating on Dublin, Ireland-based Mallinckrodt PLC and revised the outlook to negative from stable. We will review the issue-level and recovery ratings when more detail

  
Brief Excerpt:

...+ Mallinckrodt PLC is acquiring Therakos Inc. for $1.325 billion in a mostly debt-financed transaction. + We now expect pro forma leverage of almost 5x by the end of 2016, modestly higher than our prior base-case scenario. + We are affirming our '##-' corporate credit rating, but revising the outlook to negative from stable. + The negative outlook reflects risks to our base case that Mallinckrodt will not be able to reduce leverage to less than 5x by the end of 2016. NEW YORK (Standard & Poor's) Aug. 11, 2015--Standard & Poor's Ratings Services today affirmed its '##-'corporate credit rating on Dublin, Ireland-based Mallinckrodt PLC and revised the outlook to negative from stable. We will review the issue-level and recovery ratings when more detail surrounding the financing plan and capital structure becomes available. "The rating affirmation reflects Mallinckrodt's recent financial performance that is exceeding our expectations, giving the company capacity to fund this acquisition which...

  
Report Type:

Ratings Action

Issuer
GICS
Pharmaceuticals (35202010)
Sector
Global Issuers
Country
Region
Europe, Middle East, Africa
Format:
PDF Adobe Acrobat
Buy Now

S&P Global Ratings’ Credit Research—S&P Global Ratings’ credit research provides analysis on issuers and debt obligations of corporations, states and municipalities, financial institutions, insurance companies and sovereign governments. S&P Global Ratings also offers insight into the credit risk of structured finance deals, providing an independent view of credit risk associated with a growing array of debt-securitized instruments.

About the Author


Cite this Report

  
MLA:
S&P Global Ratings’ Credit Research. "Mallinckrodt PLC Outlook Revised To Negative From Stable; 'BB-' Corp. Credit Rating Affirmed" Aug 11, 2015. Alacra Store. May 04, 2025. <http://www.alacrastore.com/s-and-p-credit-research/Mallinckrodt-PLC-Outlook-Revised-To-Negative-From-Stable-BB-Corp-Credit-Rating-Affirmed-1432804>
  
APA:
S&P Global Ratings’ Credit Research. (). Mallinckrodt PLC Outlook Revised To Negative From Stable; 'BB-' Corp. Credit Rating Affirmed Aug 11, 2015. New York, NY: Alacra Store. Retrieved May 04, 2025 from <http://www.alacrastore.com/s-and-p-credit-research/Mallinckrodt-PLC-Outlook-Revised-To-Negative-From-Stable-BB-Corp-Credit-Rating-Affirmed-1432804>
  
US$ 150.00
$  £  
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Credit Research from one place.